Charles Schwab’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$164M Buy
773,711
+12,921
+2% +$2.54M 0.02% 538
2026
Q1
$149M Buy
760,790
+9,736
+1% +$1.89M 0.02% 537
2025
Q4
$130M Buy
751,054
+4,003
+0.5% +$729K 0.02% 585
2025
Q3
$142M Buy
747,051
+492
+0.1% +$87.3K 0.02% 528
2025
Q2
$134M Buy
746,559
+5,721
+0.8% +$994K 0.02% 543
2025
Q1
$125M Buy
740,838
+4,405
+0.6% +$724K 0.02% 547
2024
Q4
$111M Buy
736,433
+28,333
+4% +$4.41M 0.02% 606
2024
Q3
$110M Buy
708,100
+12,565
+2% +$1.88M 0.02% 607
2024
Q2
$95.2M Buy
695,535
+15,210
+2% +$2.08M 0.02% 672
2024
Q1
$90.6M Buy
680,325
+16,408
+2% +$2.13M 0.02% 648
2023
Q4
$91.5M Buy
663,917
+17,085
+3% +$2.25M 0.02% 599
2023
Q3
$78.8M Buy
646,832
+6,221
+1% +$829K 0.02% 609
2023
Q2
$90M Sell
640,611
-5,610
-0.9% -$773K 0.03% 560
2023
Q1
$91.4M Sell
646,221
-1,842
-0.3% -$264K 0.03% 545
2022
Q4
$101M Sell
648,063
-20,901
-3% -$3M 0.03% 476
2022
Q3
$82.1M Buy
668,964
+23,060
+4% +$3.04M 0.03% 510
2022
Q2
$85.9M Buy
645,904
+12,777
+2% +$1.74M 0.03% 511
2022
Q1
$86.7M Buy
633,127
+7,122
+1% +$993K 0.03% 576
2021
Q4
$108M Buy
626,005
+17,367
+3% +$2.64M 0.03% 496
2021
Q3
$88.4M Sell
608,638
-22,880
-4% -$3.35M 0.03% 550
2021
Q2
$83.3M Buy
631,518
+9,795
+2% +$1.28M 0.03% 587
2021
Q1
$79.8M Buy
621,723
+9,815
+2% +$1.21M 0.03% 579
2020
Q4
$72.9M Buy
611,908
+3,164
+0.5% +$386K 0.03% 565
2020
Q3
$69.7M Sell
608,744
-26,301
-4% -$3.11M 0.03% 480
2020
Q2
$72.4M Sell
635,045
-17,396
-3% -$1.85M 0.04% 467
2020
Q1
$52.4M Buy
652,441
+3,516
+0.5% +$364K 0.03% 509
2019
Q4
$69.3M Buy
648,925
+11,300
+2% +$1.18M 0.04% 462
2019
Q3
$68.2M Buy
637,625
+8,049
+1% +$826K 0.04% 430
2019
Q2
$64.1M Buy
629,576
+17,950
+3% +$1.72M 0.04% 454
2019
Q1
$55M Buy
611,626
+15,322
+3% +$1.33M 0.04% 502
2018
Q4
$49.7M Buy
596,304
+2,416
+0.4% +$227K 0.04% 453
2018
Q3
$64.1M Buy
593,888
+53,969
+10% +$5.92M 0.04% 406
2018
Q2
$59.4M Buy
539,919
+10,066
+2% +$1.05M 0.04% 422
2018
Q1
$53.1M Buy
529,853
+10,873
+2% +$1.11M 0.04% 447
2017
Q4
$51.1M Buy
518,980
+8,866
+2% +$840K 0.04% 439
2017
Q3
$47.8M Buy
510,114
+22,798
+5% +$2.42M 0.04% 435
2017
Q2
$54.2M Buy
487,316
+18,968
+4% +$2.01M 0.05% 359
2017
Q1
$46M Buy
468,348
+18,337
+4% +$1.75M 0.05% 392
2016
Q4
$41.4M Buy
450,011
+1,071
+0.2% +$92.3K 0.05% 386
2016
Q3
$38M Buy
448,940
+3,955
+0.9% +$332K 0.04% 404
2016
Q2
$36.2M Buy
444,985
+7,619
+2% +$580K 0.05% 405
2016
Q1
$31.3M Sell
437,366
-98,725
-18% -$6.62M 0.04% 444
2015
Q4
$38.1M Buy
536,091
+18,751
+4% +$1.26M 0.05% 349
2015
Q3
$31.8M Buy
517,340
+2,982
+0.6% +$208K 0.05% 378
2015
Q2
$37.3M Buy
514,358
+5,974
+1% +$441K 0.05% 362
2015
Q1
$39.1M Buy
508,384
+38,373
+8% +$2.75M 0.05% 337
2014
Q4
$31.5M Buy
470,011
+31,661
+7% +$2M 0.05% 375
2014
Q3
$26.6M Buy
438,350
+16,005
+4% +$986K 0.04% 402
2014
Q2
$24.8M Buy
422,345
+17,074
+4% +$1,000K 0.04% 413
2014
Q1
$23.5M Buy
405,271
+64,219
+19% +$3.44M 0.04% 411
2013
Q4
$18.3M Buy
341,052
+6,472
+2% +$384K 0.03% 458
2013
Q3
$20.8M Buy
334,580
+10,371
+3% +$621K 0.04% 397
2013
Q2
$19.6M Buy
+324,209
New +$19.3M 0.04% 385

Other funds holding DGX

Charles Schwab's DGX Position: Q2 2026 in Review

Charles Schwab increased its Quest Diagnostics (DGX) stake by 1.7% in Q2 2026, buying an estimated $2.54M and bringing the position to 773,711 shares worth $164M. The position accounts for 0.02% of the portfolio, ranked #538.

Charles Schwab first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. 1,103 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Charles Schwab held 773,711 shares of Quest Diagnostics worth $164M as of Q2 2026.
  • Charles Schwab bought 12,921 Quest Diagnostics shares in Q2 2026, an estimated $2.54M.
  • Quest Diagnostics made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #538 holding.
  • Charles Schwab first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • 1,103 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.